Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tabalumab pharmacokinetics by prefilled syringe versus auto-injector in rheumatoid arthritis
2012-001618-40Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tabalumab in rheumatoid arthritis (RA) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Effect of delivery system on Cmax and Effect of delivery system on AUC(0-14 days). Started Aug 2012; status: terminated.
02
Drugs
tabalumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2012-001618-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001618-40.